Microsoft AI Diagnosis Tool Beats Generalists in Science Study
Microsoft's MAI-DxO hit 83% on hard NEJM cases vs 36% for generalist doctors in a Science paper, but it's untested on patients and FDA rules are unclear.
Artificial intelligence is moving rapidly from research labs into hospitals, clinics, and patient-facing apps, and the U.S. Food and Drug Administration is under pressure to keep pace. This hub tracks how regulators, manufacturers, and clinicians are navigating the approval, oversight, and real-world deployment of AI-powered medical technologies—from diagnostic imaging tools to generative AI systems that draft clinical notes or support treatment decisions.
The stakes are rising because AI in healthcare no longer fits neatly into traditional device categories. Software that learns and adapts over time, generative models that produce open-ended clinical text, and platforms built on patient-generated data all challenge a regulatory framework designed for static, hardware-based devices. As adoption accelerates across radiology, documentation, and patient engagement, questions about safety, transparency, liability, and data ownership are becoming harder to defer.
Readers here will find coverage of how the FDA is adapting its review processes and risk frameworks for adaptive and generative AI tools, how individual companies are testing the boundaries of existing rules, and how clinicians are weighing the benefits of AI assistance against risks of overreliance or error. The hub also covers efforts—by patients, startups, and decentralized data initiatives—to reshape who controls health data and how it fuels AI development.
Together, these threads capture a pivotal moment: the FDA and the broader healthcare ecosystem are working out, often in real time, what responsible AI oversight looks like when innovation is outpacing regulation. This page will continue to track that evolving balance as new tools, policies, and controversies emerge.
Microsoft's MAI-DxO hit 83% on hard NEJM cases vs 36% for generalist doctors in a Science paper, but it's untested on patients and FDA rules are unclear.
Microsoft's MAI-DxO diagnosed 83% of complex NEJM cases vs 36% for generalist doctors in a Science study. It was a text-only benchmark, not a clinical trial.
A Science study found Microsoft's MAI-DxO diagnosed hard cases with 83% accuracy vs 36% for generalist doctors. Hospital trials come next, but FDA rules lag.
A new systematic review finds US hospital AI is outpacing oversight, citing four gaps from weak post-market monitoring to unclear liability.
FDA AI device list tops 1,600 entries, mostly radiology, and the agency kept 510(k) review for imaging AI, while hospitals now carry most clinical AI oversight.
With FDA's AI device list above 1,600, experts say hospitals must test clinical AI inside real workflows, monitor it after launch and rehearse outage plans.
Northwestern Medicine embedded OpenEvidence's AI evidence tool in Epic on Oct. 8, giving nurses and pharmacists access as FDA rules leave such tools unreviewed.
Kaiser, Cleveland Clinic, HCA and Mayo lead hospital AI as the FDA's AI device list reaches 1,614, 76% in radiology, and January rules loosen oversight.
A multicenter study in European Radiology finds DeepHealth's FDA-cleared Prostate AI, combined with radiologist MRI reads, could avoid 18.9% of biopsies while
xAID published its own ranking of seven AI radiology platforms for teleradiology groups and placed itself first, ahead of Aidoc, Viz.ai, Rad AI and Qure.ai.
Imaging AI shows trial-backed accuracy gains and FDA counts exceed 1,600 devices, while chatbots lag and new guidance shifts AI vetting to hospitals.
The FDA has now authorized over 1,600 AI medical devices, 76% of them in radiology. Hospitals use AI widely, but fewer than 20% use it well for core diagnosis.
Health systems signed enterprise AI deals in 2026 as FDA-listed AI devices hit 1,614, mostly radiology, and new FDA guidance eased decision-support oversight.
A Northwell study of 3,856 brain CT scans found Aidoc's FDA-cleared AI flagged 55 aneurysms radiologists missed, a 39% gain, but fell short in outpatient care.
FDA has cleared 1,451 AI medical devices as insurers and lawyers weigh untested malpractice liability risks heading into 2026.
FDA AI device clearances have topped 1,000, but research shows hospitals are adopting AI faster than evidence and governance can keep pace.
A Harvard-led Science study finds AI beat doctors on diagnosis and ER triage tasks, fueling debate over regulation and clinical readiness.
FDA opened public comment on regulating generative AI medical devices, proposing risk tiers and doctor-style competency testing by Oct. 19, 2026.
BioGen AI's MedSense claims to outdiagnose doctors, fueling debate over AI's expanding, loosely regulated role in hospitals.
Intermountain Medical Center becomes the second US hospital to deploy an AI-enhanced MRI machine that speeds scans and sharpens images.
Democrats sign an AI regulation pledge as the FDA seeks feedback on AI medical devices amid mental health AI lawsuits and healthcare ROI debates.
A Pennsylvania lawsuit and new FDA feedback push highlight gaps in mental health AI oversight and trust.
AI radiology tools promise faster reports amid a radiologist shortage, but FDA oversight and outcome data still lag behind adoption.
AI's rapid healthcare adoption faces scrutiny after a Mayo Clinic lawsuit alleges a 67% diagnostic error rate, raising oversight concerns.
A federal lawsuit alleges Mayo Clinic's AI diagnostic tool had a 67% error rate, fueling scrutiny of AI's growing role in health care.
Hyderabad's Mayura Hospitals won a Digital Health Innovation Award for its AI diabetes model, but published coverage of the award cites no outcome data.
A nurse's viral video says AI now drafts and summarizes EHR notes. Ambient charting tools are spreading to bedside nurses while largely escaping FDA oversight.
Google's Pixel Watch now sends AI blood pressure and insulin resistance trends as wellness features, avoiding FDA review under looser 2026 rules.
FDA proposes doctor-like competency testing for generative AI medical devices as approvals and safety concerns both rise.
FDA opens public feedback on AI-enabled medical devices as scrutiny grows over safety and diagnostic breakthroughs.